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Using laser-captured microdissection and a real-time RT–PCR assay, we quantitatively evaluated mRNA levels of the following
biomarkers in paraffin-embedded gastric cancer (GC) specimens obtained by surgical resection or biopsy: excision repair cross-
complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase (DPD), methylenetetrahydrofolate reductase (MTHFR),
epidermal growth factor receptor (EGFR), and five other biomarkers related to anticancer drug sensitivity. The study group
comprised 140 patients who received first-line chemotherapy for advanced GC. All cancer specimens were obtained before
chemotherapy. In patients who received first-line S-1 monotherapy (69 patients), low MTHFR expression correlated with a higher
response rate (low: 44.9% vs high: 6.3%; P¼0.006). In patients given first-line cisplatin-based regimens (combined with S-1 or
irinotecan) (43 patients), low ERCC1 correlated with a higher response rate (low: 55.6% vs high: 18.8%; P¼0.008). Multivariate
survival analysis of all patients demonstrated that high ERCC1 (hazard ratio (HR): 2.38 (95% CI: 1.55–3.67)), high DPD (HR: 2.04
(1.37–3.02)), low EGFR (HR: 0.34 (0.20–0.56)), and an elevated serum alkaline phosphatase level (HR: 1.00 (1.001–1.002)) were
significant predictors of poor survival. Our results suggest that these biomarkers are useful predictors of clinical outcomes in patients
with advanced GC.
British Journal of Cancer (2008) 98, 832–839. doi:10.1038/sj.bjc.6604211 www.bjcancer.com
Published online 29 January 2008
& 2008 Cancer Research UK
Keywords: gastric cancer; excision repair cross-complementing gene 1; dihydropyrimidine dehydrogenase; epidermal growth factor
receptor; prognostic factor
                                                       
Gastric cancer (GC) is the second leading cause of cancer-related
deaths worldwide, annually accounting for 40–50 deaths per
100000 population in Japan and 5–15 deaths per 100000
population in Europe (Parkin, 2001). During the past decade,
newly developed cytotoxic drugs have been included in treatment
regimens for GC. These new regimens have better response rates,
often at the cost of higher incidences of severe adverse events
(Ajani, 2005). This situation has created a greater need for
diagnostic techniques that can predict clinical outcomes such as
tumour response and survival in GC (Ichikawa, 2006). Consider-
able evidence suggests that the intratumour gene expressions of
drug-metabolising enzymes, DNA repair enzymes, or angiogenic
enzymes are useful predictors of treatment outcomes such as
survival and the response to anticancer drugs (Backus et al, 2000;
Ulrich et al, 2003; Marsh and McLeod, 2004). However, the clinical
significance of these biomarkers remains unclear, especially in GC.
5-Fluorouracil (5-FU) and cisplatin are key drugs for the
management of GC. Pharmacogenetic variability in metabolising
enzymes of 5-FU and folate is a major determinant of the
sensitivity to 5-FU and survival in GC (Lenz et al, 1996; Banerjee
et al, 2002; Ichikawa et al, 2004; Napieralski et al, 2005). Several
enzymes have key roles in the metabolic pathway of 5-FU and
folate (Figure 1): thymidylate synthase (TS) is a target enzyme of
5-FU; dihydropyrimidine dehydrogenase (DPD) is a degrading
enzyme of 5-FU; thymidine phosphorylase (TP) and orotate
phosphoribosyl transferase (OPRT) are important metabolic
enzymes; and dihydrofolate reductase (DHFR) and methylenete-
trahydrofolate reductase (MTHFR) participate in folate metabo-
lism. Lenz et al (1996) and Ichikawa et al (2004) have found that
high TS mRNA expression in GC could predict poor clinical
outcomes of treatment with 5-FU. Napieralski et al (2005) reported
that high DPD expression in GC may correlate with poor survival
and no response to 5-FU.
The cytotoxicity of cisplatin is attributed mainly to the
induction of DNA intrastrand, interstrand, and DNA–protein
crosslinks (Roberts and Thomson, 1979). Such DNA damage is
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sthought to be repaired by the nucleotide excision pathway.
Excision repair cross-complementing gene 1 (ERCC1) has a pivotal
role in nucleotide excision repair and may promote the develop-
ment of resistance to cisplatin (Dabholkar et al, 1992; Bramson and
Panasci, 1993). Excision repair cross-complementing gene 1 is also
associated with responses to cisplatin- and 5-FU-based chemo-
therapy in GC. Metzger et al (1998) reported that high ERCC1
expression in GC may be associated with poor survival and no
response to cisplatin.
Other studies, however, have failed to confirm such correlations
of the gene expressions of TS (Choi et al, 2001; Kwon et al, 2007),
DPD (Ishikawa et al, 2000; Miyamoto et al, 2000), and ERCC1
(Napieralski et al, 2005) with the outcomes of chemotherapy.
Further larger studies are thus required to confirm or refute
previous claims.
This study was designed to further delineate the clinical
implications of biomarkers and to identify potential predictors
of the response to chemotherapy and survival in patients with GC.
The epidermal growth factor receptor (EGFR) tyrosine kinase
family and the vascular endothelial growth factor (VEGF) super-
family are also well-known mediators of tumour cell proliferation
and tumour-related angiogenesis, which can influence tumour
biology and survival (Carmeliet and Jain, 2000; Gamboa-Dom-
inguez et al, 2004; Juttner et al, 2006). We tested the hypothesis
that the clinical outcomes of chemotherapy (response rate, time to
progression, and overall survival) in patients with advanced GC are
related to the pretreatment intratumour mRNA levels of enzymes
participating in critical pathways of drug resistance, such as 5-FU
and folate metabolism (TS, DPD, TP, OPRT, DHFR, MTHFR),
DNA repair (ERCC1), the EGFR signalling pathway (EGFR), and
tumour-related angiogenesis (VEGF-A). We also compared the
prognostic implications of these biomarkers with those of well-
recognised prognostic factors (Chau et al, 2004; Lee et al, 2007).
PATIENTS AND METHODS
Patient eligibility
Patients with a diagnosis of histologically proven advanced GC
were eligible for the study. Inclusion criteria were as follows:
unresectable, locally-advanced, or metastatic disease; no prior
chemotherapy and no prior adjuvant/neoadjuvant chemotherapy;
specimens of primary gastric adenocarcinomas were obtained
before the start of chemotherapy by surgical resection or biopsy at
the National Cancer Center Hospital (Tokyo, Japan) or National
Hospital Organization Shikoku Cancer Center (Matsuyama,
Japan); first-line chemotherapy was received at either of the
hospitals; radiographically measurable disease; and written
informed consent. The tissue samples were collected retrospec-
tively from patients who met these criteria. Measurable disease was
assessed by computed tomography. Response was evaluated
according to the standard UICC guidelines as complete response
(CR), partial response (PR), no change (NC), or progressive
disease (PD) (Hayward et al, 1978). Tumour response and survival
times as of December 2006 were confirmed in all patients. The
response rate was calculated as the ratio of (CRþPR)/
(CRþPRþNCþPD). Written informed consent was obtained
before treatment and evaluation of tumour samples. This study
was approved by the institutional review boards of both hospitals.
Clinical data
The following clinical data were included in analyses: performance
status, liver and peritoneal metastases, and laboratory data at the
start of chemotherapy, including leukocyte and lymphocyte counts
and the serum levels of alkaline phosphatase (ALP), lactate
dehydrogenase (LDH), albumin, C-reactive protein, and tumour
markers (CEA, CA19-9).
Chemotherapy
The following first-line chemotherapy regimens were administered
to the patients in our study: S-1 monotherapy (N¼69), cisplatin
plus S-1 (N¼14), cisplatin plus irinotecan (N¼29), 5-FU
monotherapy (N¼23), and other regimens (5-FU plus methotrex-
ate, N¼2; paclitaxel, N¼2; uracil/ftorafur, N¼1). For S-1
monotherapy, patients received S-1 (40mgm
 2 twice daily) on
days 1–28 of a 42-day cycle. Treatment with cisplatin plus S-1
consisted of cisplatin (60mgm
 2) on day 8 and S-1 (40mgm
 2
twice daily) on days 1–21 of a 35-day cycle. Treatment with
cisplatin plus irinotecan consisted of cisplatin (80mgm
 2) on day
1 and irinotecan (70mgm
 2) on days 1 and 15 of a 28-day cycle.
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Figure 1 5-Fluorouracil and folate metabolic pathways. Genes examined in our study are shown in bold. DPD, dihydropyrimidine dehydrogenase; DHFR,
dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; OPRT, orotate phosphoribosyl transferase; TS, thymidylate synthase; TP, thymidine
phosphorylase; . The official Human Genome Organization gene nomenclature is used. Common or alternative names for each gene can be found at http://
pharmacogenetics.wustl.edu.
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 2day
 1)
as a continuous infusion on days 1–5 of a 28-day cycle.
Laboratory methods
Ten-micrometre-thick sections obtained from identified areas with
the highest tumour-cell concentration were mounted on uncoated
glass slides. For histologic diagnosis, representative sections were
stained with haematoxylin and eosin by standard methods. Before
microdissection, sections were stained with nuclear fast red
(American MasterTech Scientific, Lodi, CA, USA). The sections
of interest were selectively isolated by laser-captured microdissec-
tion (PALM Microsystem, Leica, Wetzlar, Germany), according to
standard procedures (Bonner et al, 1997). The dissected particles
of tissue were transferred to a reaction tube containing 400mlo f
RNA lysis buffer.
The samples were homogenised and heated at 921C for 30min.
Fifty microlitres of 2 M sodium acetate was added at pH 4.0,
followed by 600ml of freshly prepared phenol/chloroform/isoamyl
alcohol (250:50:1). The tubes were placed on ice for 15min and
then centrifuged at 13000r.p.m. for 8min in a chilled (81C)
centrifuge. The upper aqueous phase was carefully removed.
Glycogen (10ml) and 300–400ml of isopropanol were added. The
tubes were chilled at  201C for 30–45min to precipitate the RNA.
The samples were washed in 500ml of 75% ethanol and air-dried
for 15min. The pellet was resuspended in 50mlo f5 m M Tris.
Finally, cDNA was prepared as described by Lord and colleagues
(Lord et al, 2000).
Quantification of nine genes of interest and an internal reference
gene (b-actin) was performed with a fluorescence-based real-time
detection method (ABI PRISM 7900 Sequence Detection System,
TaqMan
s, Perkin-Elmer (PE) Applied Biosystem, Foster City, CA,
USA) using the standard curve method. The PCR reaction mixture
consisted of 1200nM of each primer, 200nM of probe, 0.4U of
AmpliTaq gold polymerase, 200nM each of dATP, dCTP, dGTP,
and dTTP, 3.5mM of MgCl2, and 1  Taqman buffer A containing
a reference dye. The final volume of the reaction mixture was 20ml
(all reagents from PE Applied Biosystems, Foster City, CA, USA).
Cycling conditions were 501C for 2min and 951C for 10min,
followed by 46 cycles of 951C for 15s and 601C for 1min. The
primers and probes used are listed in Table 1. Gene expression
values (relative mRNA levels) are expressed as ratios (differences
between Ct values) between the gene of interest and an internal
reference gene (b-actin).
For each gene, we establish a usable Ct range for the data and
document the precision of the measurements within the usable
range. For maximum accuracy, we demonstrate that the slopes of
the plots of DCt vs Log pg. RNA for target genes and the
housekeeping gene (actin) demonstrate parallelism. Each replicate
Ct data point is the average of Ct values obtained in three PCR
reactions. To compare the results of two different TaqMan plates
with each other, the same standardised samples are analysed on
every plate.
Statistical analysis
We examined the objective tumour response to chemotherapy,
time to progression, and overall survival. Time to progression and
overall survival were calculated as the period from the start of first-
line chemotherapy until disease progression or death from any
cause, respectively. If patients were lost to follow-up, data were
censored at the date of the last evaluation.
To assess associations of gene expression levels with tumour
response, time to progression, and overall survival, the expression
levels of each gene were categorised into low and high values at
optimal cutoff points. The maximal w
2 method (Halpern, 1982;
Miller and Siegmund, 1982; Lausen and Schumacher, 1992) was
used to determine which gene expression (optimal cutoff point)
best segregated patients into poor- and good-outcome subgroups
(in terms of likelihood of response and survival). To determine the
corrected P-values on the basis of the maximal w
2 analysis, 2000
bootstrap-like simulations were used in univariate analyses to
estimate the distribution of the maximal w
2 statistics under the null
hypothesis of no association. The clinical laboratory data were
treated as continuous variables. The estimates of hazard ratios
(HRs) with 95% CIs, on the basis of a Cox proportional hazards
model, were used to provide quantitative summaries of the gene
expression data.
All reported P-values are two-sided, and the level of statistical
significance was set at Po0.010. Variables for multivariate analysis
were selected by the Stepwise Method, using a significance level of
o0.010 for entering into or remaining in the model. All analyses
were performed using the statistical software package R, version
2.4.1, and the SAS statistical package, version 9.1.3 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
A total of 140 patients were eligible for the study. Eighty-six
patients (61%) were recruited at the National Cancer Center
Hospital and 54 patients (39%) at the National Hospital
Organization Shikoku Cancer Center. Chemotherapy began in July
1997 in the first patient and in June 2004 in the last patient. The
demographic characteristics of the patients are shown in Table 2.
There were 108 (77%) men and 32 (23%) women with a median
age of 65 years. At the time of analysis, 131 (94%) patients had died
and nine (6%) patients were alive.
Table 1 Primer and probe sequences for quantitative RT–PCR
Gene Forward primer (50-30) Reverse primer (50-30) Taqman
s probe (50-30)
TS GCCTCGGTGTGCCTTTCA CCCGTGATGTGCGCAAT TCGCCAGCTACGCCCTGCTCA
DPD AGGACGCAAGGAGGGTTTG GTCCGCCGAGTCCTTACTGA CAGTGCCTACAGTCTCGAGTCTGCCAGTG
TP CCTGCGGACGGAATCCT GCTGTGATGAGTGGCAGGCT CAGCCAGAGATGTGACAGCCACCGT
OPRT TAGTGTTTTGGAAACTGTTGAGGTT CTTGCCTCCCTGCTCTCTGT TGGCATCAGTGACCTTCAAGCCCTCCT
DHFR GTCCTCCCGCTGCTGTCA GCCGATGCCCATGTTCTG TTCGCTAAACTGCATCGTCGCTGTGTC
MTHFR CGGGTTAATTACCACCTTGTCAA GCATTCGGCTGCAGTTCA TGAAGGGTGAAAACATCACCAATGCCC
ERCC1 GGGAATTTGGCGACGTAATTC GCGGAGGCTGAGGAACAG CACAGGTGCTCTGGCCCAGCACATA
EGFR TGCGTCTCTTGCCGGAAT GGCTCACCCTCCAGAAGGTT ACGCATTCCCTGCCTCGGCTG
VEGF-A AGTGGTCCCAGGCTGCAC TCCATGAACTTCACCACTTCGT TGATTCTGCCCTCCTCCTTCTGCCAT
b-Actin GAGCGCGGCTACAGCTT TCCTTAATGTCACGCACGATTT ACCACCACGGCCGAGCGG
Abbreviations: DHFR¼dihydrofolate reductase; DPD¼dihydropyrimidine dehydrogenase; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-
complementing gene 1; MTHFR¼methylenetetrahydrofolate reductase; OPRT¼orotate phosphoribosyl transferase; TP¼thymidine phosphorylase; TS¼thymidylate synthase;
VEGF-A¼vascular endothelial growth factor-A.
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sThe chemotherapy regimens received by the patients and the
response rates are also listed in Table 2. Many patients received S-1
monotherapy or cisplatin-based regimens as first-line treatment.
The response rates with first-line chemotherapies in our study
were comparable to those reported previously (Sakata et al, 1998;
Boku et al, 1999; Ohtsu et al, 2003; Ajani et al, 2006).
Gene expression levels of selected biomarkers, clinical
data, and overall survival in all patients
Gene expression levels of selected biomarkers were quantifiable in
88.6–99.3% of the 140 tumours (Table 3). Gene expression cutoff
values in terms of overall survival were defined by using the
maximal w
2 method, and corrected P-values were calculated for
each single gene. On univariate analyses, overall survival in the
study group as a whole correlated with the expression levels of
ERCC1, DPD, EGFR, and TS, the serum levels of LDH and ALP,
and performance status (Table 4). Using these significant mRNA
factors on univariate analyses, we performed combined analysis.
Patients with low mRNA expressions of ERCC1, DPD, TS, and high
expression of EGFR (N¼30) had significantly longer overall
survival than did the other patients (N¼106) (median overall
survival, 22.0 vs 11.2 months; Po0.001, log-rank test; Figure 2).
Multivariate analysis with a Cox proportional hazards model
demonstrated that high ERCC1 expression (HR: 2.38 (1.55–3.67)),
high DPD expression (HR: 2.04 (1.37–3.02)), low EGFR expression
(HR: 0.34 (0.20–0.56)), and an elevated serum ALP level (HR: 1.00
(1.001–1.002)) were significant predictors of poor survival
(Table 4).
Gene expression levels of selected biomarkers, tumour
response, and time to progression in patients treated with
S-1 monotherapy or cisplatin-based regimens as first-line
chemotherapy
To better understand the relation between mRNA levels of selected
biomarkers and treatment outcomes with each chemotherapy
regimen, we performed subgroup analyses. Gene expression cutoff
values that best segregated patients into poor- and good-response
subgroups were defined by using the maximal w
2 method.
In patients given first-line S-1 monotherapy, low MTHFR (low:
44.9% vs high: 6.3%, P¼0.006) gene expression alone correlated
with a better response (Table 5). Expressions of the other
eight genes did not correlate with response. In patients treated
with first-line cisplatin-based regimens (combined with S-1 or
irinotecan), low ERCC1 (low: 55.6% vs high: 18.8%, P¼0.008) gene
expression alone correlated with a better response (Table 5).
Expressions of the other eight genes did not show any correlation
with response.
Gene expression cutoff values and the corrected P-values for
time to progression analyses were determined by the same
methods as those used in the analyses of overall survival. In
patients given first-line S-1 monotherapy, expression levels of
DHFR and EGFR were significantly associated with the time to
progression (Table 6). When 2.89 10
 3 was used as the cutoff
value for DHFR, the median time to progression was 6.1 months in
the low-expression group and 4.0 months in the high-expression
group (corrected log-rank P¼0.003, HR: 2.43 (95% CI: 1.37–
4.29)). DHFR gene expression correlated with TS expression, with
a Spearman’s rank correlation coefficient of 0.456 (Po0.001).
When a cutoff value of 0.33 10
 3 was used for EGFR, the median
time to progression was significantly longer in the high EGFR
expression group (low: 2.8 months vs high: 5.3 months, P¼0.007,
HR: 0.31 (0.16–0.62)). The association between expression levels
of TS, DPD, TP, OPRT, MTHFR, ERCC1, and VEGF-A and the time
to progression did not show significant results (Table 6).
In patients who received cisplatin-based regimens as first-line
chemotherapy, expression levels of DPD and MTHFR correlated
with the time to progression (Table 6). At a DPD cutoff value of
1.55 10
 3, the median time to progression was 4.6 months in the
Table 2 Patient characteristics
Patients
Characteristic No. %
All patients 140
Sex
Male 108 77
Female 32 23
Age (years)
Median 65
Range 18–87
ECOG performance status
07 0 5 0
16 2 4 4
28 6
Metastatic site
Lymph nodes 87 62
Peritoneum 43 31
Liver 43 31
Lung 8 6
Other 9 6
Histological type
Intestinal 60 43
Diffuse 80 57
First-line chemotherapy regimen (Response rate
a (95% CI))
S-1 69 34.8 (23.7–47.2)
Cisplatin+S-1 14 35.7 (12.8–64.9)
Cisplatin+irinotecan 29 44.8 (26.5–64.3)
5-FU 23 4.3 (0.1–22.0)
5-FU+methotrexate 2 0
Paclitaxel 2 50.0 (1.3–98.7)
Uracil/ftorafur (UFT
s)1 0
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aResponse rate was
calculated as the ratio of (CR+PR)/(CR+PR+NC+PD).
Table 3 Gene expression levels of analysed biomarkers in all 140
patients
mRNA expression levels relative
to b-actin ( 10
 3)
Gene
No. of
patients (%) Median Range
TS 139 (99.3) 2.81 0.84–16.05
DPD 134 (95.7) 0.85 0.07–13.54
TP 139 (99.3) 5.96 0.82–32.01
OPRT 138 (98.6) 0.99 0.28–4.55
DHFR 124 (88.6) 2.94 0.42–8.69
MTHFR 136 (97.1) 1.24 0.25–8.20
ERCC1 139 (99.3) 1.03 0.22–6.22
EGFR 126 (90.0) 1.24 0.12–57.78
VEGF-A 137 (97.9) 4.89 1.07–30.23
Abbreviations: DHFR¼dihydrofolate reductase; DPD¼dihydropyrimidine dehydro-
genase; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-
complementing gene 1; MTHFR¼methylenetetrahydrofolate reductase;
OPRT¼orotate phosphoribosyl transferase; TP¼thymidine phosphorylase;
TS¼thymidylate synthase; VEGF-A¼vascular endothelial growth factor-A.
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the high DPD expression group (P¼0.008, HR: 4.87 (1.75–13.53)).
At a MTHFR cutoff value of 0.94 10
 3, the median time to
progression was significantly longer in the high-expression group
(low: 2.9 months vs high: 5.9 months, P¼0.007, HR: 0.17 (0.07–
0.42)). The association between expression levels of the other seven
genes and time to progression did not show significant results
(Table 6).
DISCUSSION
In this study, we analysed mRNA expression levels of nine genes
involved in 5-FU and folate metabolism, DNA repair, and
angiogenesis in primary tumours from 140 patients with advanced
GC. Our goal was to determine whether such expression levels are
related to treatment outcomes such as survival and response. We
found that high DPD expression, high ERCC1 expression, and low
EGFR expression in GC specimens were significant predictors of
poor survival in advanced GC. Recently, several studies have
reported that patients’ genetic profiles are related to the outcomes
of cancer therapy (van ‘t Veer et al, 2002; Ruzzo et al, 2006).
In colorectal cancer, since many studies have examined molecular
predictors of outcomes during the past decade, TS, DPD, and TP
were newly included in ‘ASCO 2006 tumour marker guidelines in
gastrointestinal cancer’ (Locker et al, 2006). Because sufficient
supporting evidence is lacking, however, the guidelines recom-
mend that these biomarkers should not yet be used clinically to
predict prognosis or treatment response. Further studies are
therefore needed to more clearly define the relation between
mRNA expression levels and clinical outcomes.
Our study showed that gene expression levels of DPD (related to
the pharmacokinetics of fluoropyrimidines) and ERCC1 (related to
the pharmacodynamics of cisplatin) had significant impacts on
the overall survival of patients with advanced GC. This finding is
consistent with the results of previous investigations (Metzger
et al, 1998; Terashima et al, 2002; Napieralski et al, 2005). S-1, an
oral DPD inhibitory fluoropyrimidine, is a novel antitumour drug
Table 4 Univariate analysis and Cox regression multivariate analysis of overall survival in all patients included in this study: correlation with mRNA
expression levels and clinical data
Univariate analysis Multivariate analysis
Factor
a Cut point No. of patients Median (months) Hazard ratio (95% CI) P Hazard ratio (95% CI) P
LDH Continuous — — — o0.001
Variable 1.00 (1.000–1.001)
ALP Continuous — — — o0.001 — o 0.001
Variable 1.00 (1.001–1.002) 1.00 (1.001–1.002)
ERCC1 p1.42 10
 3 103 14.3 1 0.002 1 o 0.001
41.42 10
 3 36 9.8 2.12 (1.41–3.18) 2.38 (1.55–3.67)
DPD p1.18 10
 3 93 14.5 1 0.003 1 o 0.001
41.18 10
 3 44 10.2 1.95 (1.34–2.83) 2.04 (1.37–3.02)
PS Continuous — — — 0.004
Variable 1.55 (1.15–2.08)
EGFR p0.33 10
 3 21 8.2 1 0.005 1 o 0.001
40.33 10
 3 118 13.6 0.42 (0.26–0.69) 0.34 (0.20–0.56)
TS p2.61 10
 3 62 16.0 1 0.010
42.61 10
 3 77 11.2 1.64 (1.15–2.34)
Abbreviations: ALP¼alkaline phosphatase; DPD¼dihydropyrimidine dehydrogenase; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-complementing
gene 1; LDH¼lactate dehydrogenase; PS¼performance status; TS¼thymidylate synthase. Note: ‘Cutoff point’ for mRNA expression level was determined by the maximal w
2
method.
aFactors with P-values of o0.010 in univariate analyses are listed in ascending order of P-values. The stepwise method was used to select factors for multivariate analysis.
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Figure 2 Kaplan–Meier plot of overall survival for all patients according to ERCC1, DPD, TS, and EGFR mRNA expression levels.
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scombining tegafur (FT: a prodrug of 5-FU), gimeracil (CDHP:
5-chloro-2,4 dihydropyridine), and oteracil (Oxo: potassium
oxonate) (Shirasaka et al, 1993, 1996). CDHP inhibits DPD activity
and therefore prevents fluoropyrimidine degradation (Shirasaka
et al, 1996). Oxo is a gastrointestinal tract adverse effect modulator
(Shirasaka et al, 1993). In Japan, S-1 as monotherapy or combined
with cisplatin is a standard regimen for advanced GC (Sakata et al,
1998; Ajani et al, 2006). Boku et al (2007) reported the result of a
randomised controlled trial showing that S-1 is a promising
standard regimen as compared with 5-FU, and Narahara et al
(2007) showed that S-1 plus cisplatin is superior to S-1 alone. A
multinational phase III study comparing S-1 plus cisplatin with 5-
FU plus cisplatin (control regimen) is now underway. In the future,
S-1 combined with cisplatin may become a standard regimen not
only in Japan but also worldwide. In our study, 129 patients (92%)
received S-1- or 5-FU-based regimens, and 73 patients (52%)
received cisplatin-based regimens as first-line or subsequent
chemotherapy. Our results strongly suggest that tumours with
high DPD and ERCC1 gene expression are unlikely to respond to
current standard therapy, resulting in inadequate tumour control
and poor outcomes. Patients with such tumours would require
newly developed drugs and combined treatment modalities
tailored to their specific needs.
Patients with low DHFR expression had a higher response rate
and a longer time to progression while receiving S-1 monotherapy
(Tables 5 and 6). DHFR is a key enzyme of folate metabolism.
DHFR converts intracellular inactive dihydrofolate back to active
tetrahydrofolate, which is reused in deoxythymidine-50-monophos-
phate synthesis (Figure 1) and is crucial for 5-FU antitumour
activity. Sowers et al (2003) reported that E2F transcription factors
Table 5 Gene expression levels and tumour response in patients with advanced gastric cancer according to first-line chemotherapy
S-1 monotherapy (N¼69) Cisplatin-based regimens
a (N¼43)
Factor
Total no. of
patients
Cut point
( 10
 3)
RR (%) in low
group
RR (%) in
high group P
Total no. of
patients
Cut point
( 10
 3)
RR (%) in low
group
RR (%) in
high group P
TS 66 3.67 45.2 (19/42) 20.8 (5/24) 0.044 43 3.43 50.0 (15/30) 23.1 (3/13) 0.103
DPD 65 0.83 25.9 (7/27) 44.7 (17/38) 0.119 42 0.84 28.0 (7/25) 58.8 (10/17) 0.041
TP 66 5.37 25.9 (7/27) 43.6 (17/39) 0.121 43 7.81 32.1 (9/28) 60.0 (9/15) 0.049
OPRT 65 0.61 0 (0/6) 39.0 (23/59) 0.059 43 0.94 57.1 (12/21) 27.3 (6/22) 0.029
DHFR 59 1.64 57.1 (4/7) 28.8 (15/52) 0.105 39 2.32 31.6 (6/19) 45.0 (9/20) 0.323
MTHFR 65 1.82 44.9 (22/49) 6.3 (1/16) 0.006 43 1.15 52.2 (12/23) 30.0 (6/20) 0.152
ERCC1 65 0.92 50.0 (14/28) 24.3 (9/37) 0.033 43 1.18 55.6 (15/27) 18.8 (3/16) 0.008
EGFR 66 1.20 45.7 (16/35) 25.8 (8/31) 0.094 43 1.39 51.7 (15/29) 21.4 (3/14) 0.049
VEGF-A 65 2.70 54.5 (6/11) 31.5 (17/54) 0.104 43 6.52 53.8 (14/26) 23.5 (4/17) 0.022
Abbreviations: DHFR¼dihydrofolate reductase; DPD¼dihydropyrimidine dehydrogenase; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-
complementing gene 1; MTHFR¼methylenetetrahydrofolate reductase; OPRT¼orotate phosphoribosyl transferase; RR¼response rate; TP¼thymidine phosphorylase;
TS¼thymidylate synthase; VEGF-A¼vascular endothelial growth factor-A. Note: ‘Cutoff point’ was determined by the maximal w
2 method. The level of significance was set at
Po0.010. Significant values are shown in bold.
aCisplatin-based regimens: cisplatin+S-1 and cisplatin+irinotecan.
Table 6 Univariate analyses of time to progression in patients with advanced gastric cancer treated with S-1 monotherapy or cisplatin-based regimens as
first-line chemotherapy: correlation with mRNA expression levels
S-1 monotherapy (N¼69) Cisplatin-based regimens
a (N¼43)
Factor
Cut point
( 10
 3)
No. of
patients
Median
(months)
Hazard ratio
(95% CI) P
Cut point
( 10
 3)
No. of
patients
Median
(months)
Hazard ratio
(95% CI) P
TS p5.27 60 4.5 1 0.131 p3.36 29 5.4 1 0.140
45.27 9 4.2 2.11 (0.97–4.55) 43.36 14 3.9 1.68 (0.87–3.24)
DPD p1.57 51 4.9 1 0.080 p1.55 37 4.6 1 0.008
41.57 17 4.0 1.90 (1.06–3.43) 41.55 5 1.2 4.87 (1.75–13.53)
TP p5.58 31 4.0 1 0.207 p8.31 30 4.2 1 0.222
45.58 38 5.1 0.72 (0.44–1.18) 48.31 13 6.2 0.62 (0.32–1.22)
OPRT p1.44 48 4.2 1 0.223 p0.92 20 6.2 1 0.036
41.44 20 4.2 1.37 (0.79–2.36) 40.92 23 3.9 1.93 (1.02–3.66)
DHFR p2.89 29 6.1 1 0.003 p5.82 35 4.5 1 0.215
42.89 33 4.0 2.43 (1.37–4.29) 45.82 4 14.6 0.41 (0.12–1.39)
MTHFR p1.04 20 2.9 1 0.158 p0.94 10 2.9 1 0.001
41.04 48 5.1 0.59 (0.34–1.01) 40.94 33 5.9 0.17 (0.07–0.42)
ERCC1 p1.30 49 4.2 1 0.370 p1.12 24 4.2 1 0.318
41.30 19 4.4 0.72 (0.41–1.27) 41.12 19 5.9 0.75 (0.41–1.39)
EGFR p0.33 12 2.8 1 0.007 p0.81 16 3.9 1 0.158
40.33 57 5.3 0.31 (0.16–0.62) 40.81 27 5.2 0.53 (0.28–1.03)
VEGF-
A
p2.45 7 1.9 1 0.193 p7.86 34 3.8 1 0.130
42.45 61 4.4 0.46 (0.21–1.02) 47.86 9 7.2 0.43 (0.20–0.93)
Abbreviations: DHFR¼dihydrofolate reductase; DPD¼dihydropyrimidine dehydrogenase; EGFR¼epidermal growth factor receptor; ERCC1¼excision repair cross-
complementing gene 1; MTHFR¼methylenetetrahydrofolate reductase; OPRT¼orotate phosphoribosyl transferase; TP¼thymidine phosphorylase; TS¼thymidylate synthase;
VEGF-A¼vascular endothelial growth factor-A. Note: ‘Cutoff point’ was determined by the maximal w
2 method. The level of significance was set at Po0.010. Significant values
are shown in bold.
aCisplatin-based regimens: cisplatin+S-1 and cisplatin+irinotecan.
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We showed that a Spearman’s correlation coefficient for TS/DHFR
was 0.456 (Po0.001). Backus et al (2000) reported that low TS
expression in vitro correlated with increased sensitivity to 5-FU.
Several clinical studies have found that patients with low TS gene
expression in primary GC correlate with a better tumour response
and longer survival after 5-FU or S-1 treatment (Lenz et al, 1996;
Ichikawa et al, 2004). The results of these studies suggest that low
DHFR expression is associated with better clinical outcomes in
patients given S-1 monotherapy, consistent with the results of our
study. DHFR might thus be a candidate predictive biomarker of
the response to S-1 treatment. Our data suggested that low DHFR
expression may be an important determinant of tumour-cell
sensitivity to S-1.
In patients who received S-1 monotherapy, low MTHFR gene
expression also correlated with a better tumour response (Table 5).
Some studies have reported that the MTHFR 677T mutation, linked
to the reduced activity of MTHFR, increases chemosensitivity to
5-FU (Cohen et al, 2003; Sohn et al, 2004), whereas others have
had inconsistent results (Etienne et al, 2004; Ruzzo et al, 2006).
Although MTHFR and DHFR are key enzymes in folate
metabolism, the role of MTHFR gene expression in the antitumour
activity of 5-FU remains controversial.
In patients given cisplatin-based regimens as first-line chemo-
therapy, low ERCC1 mRNA expression alone correlated with a
better tumour response, confirming a previously reported
association (Metzger et al, 1998). With respect to EGFR gene
expression, evidence supporting a correlation between mRNA
expression levels and survival or time to progression in GC is
scant. Vallbohmer et al (2006) reported that high mRNA
expression of EGFR was associated with a better response as well
as longer progression-free and overall survival in patients with
colorectal cancer who received irinotecan therapy, which is
partially in accord with our findings. In contrast, Gamboa-
Dominguez et al (2004) found that strong membranous staining
of EGFR on immunohistochemical analysis correlated with poor
survival. The clinical implications of EGFR gene expression thus
remain controversial.
In conclusion, our study provides evidence that high DPD, high
ERCC1, and low EGFR gene expression levels in GC specimens and
an elevated serum ALP level are risk factors for poor survival in
patients with advanced GC. To the best of our knowledge, this is
the first study showing that mRNA expression levels of molecular
markers in primary GC had as much impact on survival outcomes
as did well-recognised prognostic factors. The results of our
analysis will hopefully provide a more rational basis for clinical
decision-making, risk stratification of patients, and selection of
management strategies as well as suggest benchmarks for future
randomised controlled trials. Our relatively small sample size
precludes drawing any firm conclusions, and candidate bio-
markers must be validated in prospective studies. To confirm and
extend the results of this exploratory study, larger studies are being
planned in Japan.
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